Kyverna appoints Nadia Dac chief commercial officer

• Kyverna Therapeutics appointed Nadia Dac as chief commercial officer, effective May 4.
• Dac will lead commercial strategy for mivocabtagene autoleucel (KYV-101) as company prepares for a potential first approval in stiff person syndrome, with planned expansion into other neuroimmunology diseases.
• She most recently served as chief commercial officer at Omeros, where she built commercial operations for rare disease programs, including launch of Yartemlea.
• Earlier roles include chief commercial officer at Alder Biopharmaceuticals for launch of Vyepti, vice president of global specialty commercial development at AbbVie, with prior commercial leadership posts at Novartis and Biogen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-202610), on May 04, 2026, and is solely responsible for the information contained therein.